Dianthus Therapeutics (Dianthus Therapeutics) Other Long Term Assets : $0.81 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Dianthus Therapeutics Other Long Term Assets?

Dianthus Therapeutics's other long-term assets for the quarter that ended in Mar. 2024 was $0.81 Mil.

Dianthus Therapeutics's quarterly other long-term assets increased from Sep. 2023 ($0.12 Mil) to Dec. 2023 ($1.15 Mil) but then stayed the same from Dec. 2023 ($1.15 Mil) to Mar. 2024 ($0.81 Mil).

Dianthus Therapeutics's annual other long-term assets increased from Dec. 2021 ($0.03 Mil) to Dec. 2022 ($0.12 Mil) and increased from Dec. 2022 ($0.12 Mil) to Dec. 2023 ($1.15 Mil).

Dianthus Therapeutics Other Long Term Assets Historical Data

The historical data trend for Dianthus Therapeutics's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dianthus Therapeutics Other Long Term Assets Chart

Dianthus Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Other Long Term Assets

0.03

0.12

1.15

Dianthus Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Other Long Term Assets	Get a 7-Day Free Trial			0.12	-	0.12	1.15	0.81

Dianthus Therapeutics Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Dianthus Therapeutics (Dianthus Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Dianthus Therapeutics Inc (NAS:DNTH) » Definitions » Other Long Term Assets

Comparable Companies

Traded in Other Exchanges

87E:Germany

Address

7 Times Square, 43rd Floor, New York, NY, USA, 10036

Website

https://www.dianthustx.com

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, best-in-class monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is comprised of an experienced team of biotech and pharma executives who are leading the next generation of antibody complement therapeutics, aiming to deliver transformative medicines for people living with severe autoimmune diseases.

Dianthus Therapeutics (Dianthus Therapeutics) Headlines

From GuruFocus

Fairmount Funds Management LLC Acquires New Stake in Dianthus Therapeutics Inc

By GuruFocus Research • 09-29-2023

Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc

By GuruFocus Research • 09-14-2023